Currently, there is a clinical trial of patients with ER+ breast cancer treated with a combination of three FDA-approved CDK4/6 inhibitors and anti-PD-1/PD-L1 inhibitors (NCT03294694, NCT02778685 and NCT03147287) [54]. Here, CD274 is linked to breast carcinoma.